Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly ( NYSE:LLY | LLY Price Prediction ) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the…
TR
By Tom Reyes · Markets Editor
Oct 29 11:03 ETSource: 24/7 Wall St.
From the source
Read at 247wallst.comEli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly ( NYSE:LLY | LLY Price Prediction ) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving. Eli Lilly stock is trading at $1,393, up 8%.
